<DOC>
	<DOCNO>NCT01344512</DOCNO>
	<brief_summary>The Pharm A project French national collaborative project aim determine population pharmacokinetics ceftazidime , ciprofloxacin , voriconazole paediatric patient age one month five year .</brief_summary>
	<brief_title>Population Pharmacokinetics Anti-infectious Drugs Children</brief_title>
	<detailed_description>The licensing process introduce order ensure medicine safe , effective high quality . However , 50 % child admit hospital France Europe receive unlicensed off-label medicine . This occur drug child le 6 year age . They represent particularly vulnerable subgroup paediatric population . There major practical ethical issue relation study medicine paediatric patient age 5 year less . - They represent small part population compare old child adult , variation specific type diseases young subpopulation high paediatric counterpart . There major difference drug disposition different age group . - There need suitable methodological approach clinical trial - There major ethical issue It essential , therefore , recruit child various region France order obtain critical sample size sufficient magnitude conduct scientific sound study . This achieve perform Pharm A , population pharmacokinetic study three different anti infectious agent ( ceftazidime , ciprofloxacin , voriconazole ) identify covariates include pharmacogenetic biomarkers explain pharmacokinetic variability . After parental informed consent , sample strategy randomize depend drug age group ( 2 sample patient 2 year 3 sample patient 2 5 year ) .</detailed_description>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>Children age 28 day 11 year ( &lt; 12 year ) Receiving one follow drug therapeutic reason : ceftazidime , ciprofloxacin , voriconazole Representative clinician , condition require use molecule Informed consent sign two parent legal representative Child affiliate national social security system</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Population</keyword>
	<keyword>Children</keyword>
	<keyword>Ceftazidime</keyword>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Voriconazole</keyword>
	<keyword>Pediatric</keyword>
</DOC>